Evidence map›Paper›PMID 15988677›Full record

ArticleAmerican journal of human genetics2005

A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.

Jianfeng Xu, Latchezar Dimitrov, Bao-Li Chang, Tamara S Adams, Aubrey R Turner, Deborah A Meyers, Rosalind A Eeles, Douglas F Easton, William D Foulkes, Jacques Simard and 62 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

72 authors at 8 institutions in 4 countries.

Jianfeng XuCenter for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Latchezar Dimitrov
Bao-Li Chang
Tamara S Adams
Aubrey R Turner
Deborah A Meyers
Rosalind A Eeles
Douglas F Easton
William D Foulkes
Jacques Simard
Graham G Giles
John L Hopper
Lovise Mahle
Pal Moller
Tim Bishop
Chris Evans
Steve Edwards
Julia Meitz
Sarah Bullock
Questa Hope
Chih-Lin Hsieh
Jerry Halpern
Raymond N Balise
Ingrid Oakley-Girvan
Alice S Whittemore
Charles M Ewing
Marta Gielzak
Sarah D Isaacs
Patrick C Walsh
Kathleen E Wiley
William B Isaacs
Stephen N Thibodeau
Shannon K McDonnell
Julie M Cunningham
Katherine E Zarfas
Scott Hebbring
Daniel J Schaid
Danielle M Friedrichsen
Kerry Deutsch
Suzanne Kolb
Michael Badzioch
Gail P Jarvik
Marta Janer
Leroy Hood
Elaine A Ostrander
Janet L Stanford
Ethan M Lange
Jennifer L Beebe-Dimmer
Caroline E Mohai
Kathleen A Cooney
Tarja Ikonen
Agnes Baffoe-Bonnie
Henna Fredriksson
Mika P Matikainen
Teuvo Lj Tammela
Joan Bailey-Wilson
Johanna Schleutker
Christiane Maier
Kathleen Herkommer
Josef J Hoegel
Walther Vogel
Thomas Paiss
Fredrik Wiklund
Monica Emanuelsson
Elisabeth Stenman
Bjorn-Anders Jonsson
Henrik Gronberg
Nicola J Camp
James Farnham
Lisa A Cannon-Albright
Daniela Seminara
ACTANE Consortium
Tampere University Hospital · FIJohns Hopkins University · USThe Coordinating Center · USWinnMed · USUmeå University · SEUniversität Ulm · DEUniversity of Michigan · USUniversity of Utah · US

Funding

TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI EPSTEIN, JONATHAN · 1992 to 2020
$43.9M
Prostate Cancer Susceptibility: The ICPCG StudyU01CA089600 · NCI · MAYO CLINIC ROCHESTER · PI THIBODEAU, STEPHEN NORMAN · 2002 to 2016
$27.3M
VIRAL DAMAGE TO BRAIN AND NEUROMUSCULAR SYSTEMM01RR000064 · NCRR · UNIVERSITY OF UTAH · PI SWOBODA, KATHRYN J. · 1985 to 2008
$21.7M
Interdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7M
Finding Genes for Cancer Susceptibility and Growth RegulationZ01HG200325 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI OSTRANDER, ELAINE · 2005 to 2008
$7.3M
GENETIC EPIDEMIOLOGY OF PROSTATE CANCERR01CA080122 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1999 to 2008
$3.8M
GENETIC ANALYSIS OF HEREDITARY PROSTATE CANCER FAMILIESR01CA079596 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 1999 to 2009
$3.0M
Mapping and Cloning Prostate Cancer Predisposition LociR01CA090752 · NCI · UNIVERSITY OF UTAH · PI ALBRIGHT, LISA CANNON · 2001 to 2004
$2.3M
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCERR01CA072818 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI THIBODEAU, STEPHEN NORMAN · 1997 to 2005
$1.9M
GENOTYPING FOR LOCATING HUMAN DISEASE GENESN01HG065403 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID L · 1996 to 2000
$1.7M
Genetic Epidemiology of CancerZ01HG200331 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BAILEY-WILSON, JOAN ELLEN · 2005 to 2008
$1.6M
Interaction of PTEN and CDKN1B in Pca susceptibilityR01CA106523 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI XU, JIANFENG · 2004 to 2008
$1.6M
NCI NIH HHS CA079596NCI NIH HHS CA080122NCI NIH HHS CA106523-01A1NCI NIH HHS CA58236NCI NIH HHS CA67044NCI NIH HHS CA72818NCI NIH HHS CA78835NCI NIH HHS CA89600NCI NIH HHS CA95052-01NCI NIH HHS K07 CA098364NCI NIH HHS K07 CA98364NCI NIH HHS N01 PC035141NCI NIH HHS N01-PC-35141NCI NIH HHS P50 CA058236NCI NIH HHS R01 CA067044NCI NIH HHS R01 CA072818NCI NIH HHS R01 CA079596NCI NIH HHS R01 CA080122NCI NIH HHS R01 CA090752NCI NIH HHS R01 CA095052NCI NIH HHS R01 CA106523NCI NIH HHS R01 CA89600NCI NIH HHS R01 CA90752NCI NIH HHS T32 CA080416NCI NIH HHS U01 CA067044NCI NIH HHS U01 CA089600NCRR NIH HHS M01 RR000064NCRR NIH HHS M01-RR00064NHGRI NIH HHS N01 HG065403
6 · The paper itself

Abstract

Evidence of the existence of major prostate cancer (PC)-susceptibility genes has been provided by multiple segregation analyses. Although genomewide screens have been performed in over a dozen independent studies, few chromosomal regions have been consistently identified as regions of interest. One of the major difficulties is genetic heterogeneity, possibly due to multiple, incompletely penetrant PC-susceptibility genes. In this study, we explored two approaches to overcome this difficulty, in an analysis of a large number of families with PC in the International Consortium for Prostate Cancer Genetics (ICPCG). One approach was to combine linkage data from a total of 1,233 families to increase the statistical power for detecting linkage. Using parametric (dominant and recessive) and nonparametric analyses, we identified five regions with "suggestive" linkage (LOD score >1.86): 5q12, 8p21, 15q11, 17q21, and 22q12. The second approach was to focus on subsets of families that are more likely to segregate highly penetrant mutations, including families with large numbers of affected individuals or early age at diagnosis. Stronger evidence of linkage in several regions was identified, including a "significant" linkage at 22q12, with a LOD score of 3.57, and five suggestive linkages (1q25, 8q13, 13q14, 16p13, and 17q21) in 269 families with at least five affected members. In addition, four additional suggestive linkages (3p24, 5q35, 11q22, and Xq12) were found in 606 families with mean age at diagnosis of < or = 65 years. Although it is difficult to determine the true statistical significance of these findings, a conservative interpretation of these results would be that if major PC-susceptibility genes do exist, they are most likely located in the regions generating suggestive or significant linkage signals in this large study.

Indexed as

Genetic LinkageGenetic Predisposition to DiseaseGenome, HumanAgedChromosome MappingFamily HealthGenetic MarkersGenotypeHumansInternational CooperationLod ScoreMaleMiddle AgedPedigreeProstatic NeoplasmsGenetic Markers

Identifiers

PMID15988677
PMCPMC1224525
OpenAlexW1981432474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.